Blepharitis: Clinical Trials

11 trials for Blepharitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed. 11 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 211Completed 11
Phase 31Completed 1

Follow Blepharitis: new trials by email Literature Review of Blepharitis trials Research Report on Blepharitis

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis.
APT-001 topical ophthalmic ointment (spinosad), Vehicle control for APT-001 topical ophthalmic ointment - Blepharitis
Phase 2CompletedAperta Biosciences, LLC662025-11-012026-10-27
Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
TP-03, TP-03 Vehicle - Meibomian Gland Dysfunction, Blepharitis
Phase 2CompletedTarsus Pharmaceuticals, Inc.392022-08-032025-10-01
Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis
NCX 4251, Placebo - Blepharitis
Phase 2CompletedNicox Ophthalmics, Inc.2242020-12-142023-06-18
Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
TP-03, 0.25%, TP-03 Vehicle - Blepharitis
Phase 2 / Phase 3CompletedTarsus Pharmaceuticals, Inc.4212020-09-092023-12-21
Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis
Fluticasone Propionate, Placebo - Blepharitis
Phase 2CompletedNicox Ophthalmics, Inc.362019-03-182023-06-18
Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease
KPI-121, Vehicle - Blepharitis
Phase 2CompletedKala Pharmaceuticals, Inc.2062014-07-012021-01-11
Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis
Azithromycin, Povidone - Blepharitis
Phase 2CompletedLaboratoires Thea932010-03-012014-11-04
The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)
Azithromycin ophthalmic solution, 1%, Placebo - Blepharitis
Phase 2CompletedMerck Sharp & Dohme LLC3142009-05-012013-11-21
The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period
Azithromycin ophthalmic solution, 1%, Placebo - Blepharitis
Phase 2CompletedMerck Sharp & Dohme LLC3132009-04-012011-09-26
Tea Tree Oil in the Treatment of Chronic Blepharitis
Tea Tree Oil - Blepharitis
Phase 2CompletedFederal University of São Paulo342009-04-012010-02-23
Treatment of Patients With Blepharitis and Facial Rosacea
COL-101 (doxycycline, USP) capsules, placebo - Blepharitis, Meibomianitis
Phase 2CompletedGalderma R&D702007-11-012021-02-18

Narrower conditions

Meibomian Gland Dysfunction (2)  ·  Dry Eye Syndromes (1)  ·  Meibomitis (1)  ·  Pain (1)

Broader conditions

Eye Diseases (11)  ·  Eyelid Diseases (11)  ·  Lacrimal Apparatus Diseases (1)  ·  Neurologic Manifestations (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Signs and Symptoms (1)

Interventions

Azithromycin (1)  ·  Capsules (1)  ·  Doxycycline (1)  ·  Fluticasone (1)  ·  Loteprednol Etabonate (1)  ·  Povidone (1)  ·  Tea Tree Oil (1)  ·  spinosad (1)

Sponsors

Merck Sharp & Dohme LLC (2)  ·  Nicox Ophthalmics, Inc. (2)  ·  Tarsus Pharmaceuticals, Inc. (2)  ·  Aperta Biosciences, LLC (1)  ·  Federal University of São Paulo (1)  ·  Galderma R&D (1)  ·  Kala Pharmaceuticals, Inc. (1)  ·  Laboratoires Thea (1)

Countries

United States (8)  ·  Brazil (1)  ·  France (1)  ·  Guatemala (1)

Top investigators

Nicox Ophthalmics (2)  ·  Damien Goldberg, MD (1)  ·  David Wirta, MD (1)  ·  Jodi Luchs, MD (1)  ·  John Sheppard, MD (1)  ·  Joseph Tauber, MD (1)  ·  Josue Moran, Ph.D. (1)  ·  Kelly Nichols, OD, PhD (1)  ·  Kenneth Sall, MD (1)  ·  Marc Abrams, MD (1)  ·  Michael Graeber, MD (1)  ·  Mitchell Shultz, MD (1)  ·  Nahin Geha (1)  ·  Reza Haque, MD, PhD (1)

Results publications

PMID 35965392

NIH funding

2009 (1)